Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual strategy. The business is defensive, with a diversified product mix and pipeli
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 29, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2025 ended June 30, 202

What Makes Amphastar (AMPH) a New Buy Stock

01:00pm, Wednesday, 23'rd Jul 2025
Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflectio
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be partici
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stree
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peter
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or th
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 20
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE